title: Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
abstract: Transient potential receptor melastatin-2 (TRPM2) is a nonselective cationic, Ca(2+)-permeable transmembrane pore that is preferentially expressed in cells of the myeloid lineage and modulates signaling pathways converging into NF-kB. This is of potential interest for acute myeloid leukemia (AML) therapy, as NF-κB signaling is emerging as a key pathway, mediating drug resistance and leukemia-initiating cell survival in AML. Inhibition of NF-κB signaling has been found to be synergistic with chemotherapy. TRPM2 is overexpressed in AML compared with normal bone marrow, with the highest levels in the FAB M3-6 subtypes. To determine the effect of TRPM2 depletions in a defined genetic model, we established MLL-AF9-driven AML on a Trpm2(-/-) genetic background. Trpm2(-/-) MLL-AF9 leukemias displayed reduced NF-κB phosphorylation as well as nuclear translocation. In vivo, primary and secondary recipients of Trpm2(-/-) MLL-AF9 leukemias exhibit increased latency compared with recipients of wild-type leukemia cells. However, the difference in latency was small and was lost in tertiary transplants. The effect of loss of Trpm2 in a BCR-ABL/NUP98-HOXA9 fusion model was even smaller. Given reports that loss or inhibition of TRPM2 enhanced killing by DNA-damaging agents in neuroblastoma, breast cancer, and prostate cancer cell lines, we exposed Trpm2(-/-) and Trpm2(wt) primary MLL-AF9 leukemias to doxorubicin, cytarabine, and etoposide, but found no difference in IC50 values. The in vitro response to decitabine was also unaffected. In summary, Trpm2 does not seem to play a major role in myeloid leukemogenesis. Additionally, loss of Trpm2 does not augment the cytotoxicity of standard AML chemotherapeutic agents.
authors.affiliation: Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.
authors.forename: Jessica N
authors.initials: JN
authors.lastname: Haladyna
authors.affiliation: Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.
authors.forename: Taylor
authors.initials: T
authors.lastname: Pastuer
authors.affiliation: Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO.
authors.forename: Simone S
authors.initials: SS
authors.lastname: Riedel
authors.affiliation: Department of Biomedical Research and Department of Microbiology and Immunology, National Jewish Health, Denver, CO.
authors.forename: Anne-Laure
authors.initials: AL
authors.lastname: Perraud
authors.affiliation: Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO. Electronic address: Kathrin.Bernt@ucdenver.edu.
authors.forename: Kathrin M
authors.initials: KM
authors.lastname: Bernt
mesh_terms: D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000235:genetics* / Q000378:metabolism; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D016328:NF-kappa B / Q000378:metabolism; D010766:Phosphorylation; D011379:Prognosis; D050053:TRPM Cation Channels / Q000235:genetics* / Q000378:metabolism
chemical_list: D016328:NF-kappa B; D050053:TRPM Cation Channels; C544443:TRPM2 protein, mouse